Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present disclosure relates to methods of treating metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) and castrate resistant prostate cancer (CRPC) in a patient in need thereof.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• Prostate cancer is the second most common cancer in men. With an estimated 375,304 deaths in 2020 worldwide, prostate cancer is the fifth leading cause of death from cancer in men and represents 6.8% of total cancer death in males (Sung 2021).
• ADT androgen deprivation therapy
• LHRH hormone-releasing hormone
• orchidectomy Treatment of prostate cancer with androgen deprivation therapy (ADT) such as luteinising hormone-releasing hormone (LHRH) analogues or orchidectomy is usually initially effective at controlling metastatic disease.
• ADT androgen deprivation therapy
• LHRH hormone-releasing hormone
• orchidectomy Treatment of prostate cancer with androgen deprivation therapy (ADT) such as luteinising hormone-releasing hormone (LHRH) analogues or orchidectomy is usually initially effective at controlling metastatic disease.
• LHRH hormone-releasing hormone
• patients inevitably progress from an androgen sensitive to a castration-resistant phenotype which is associated with 90% of overall mortality (Scher 2015).
• NHAs new hormonal agents
• Olaparib a PARP1/PARP2 inhibitor
• Olaparib a PARP1/PARP2 inhibitor
• enzalutamide is a strong CYP3A4 inducer (Gibbons 2015) and Olaparib is a substrate of CYP3A4 (Dirix 2016)
• co-administration of enzalutamide with Olaparib in a multiple dose setting would significantly reduce Olaparib exposure in patients.
• metastatic prostate cancer hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• mHSPC metastatic hormone sensitive prostate cancer
• mCRPC metastatic castrate resistant prostate cancer
• a method of treating metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject in need thereof comprising administering to the subject a first amount of AZD5305 or a pharmaceutically acceptable salt thereof, and a second amount of darolutamide or a pharmaceutically acceptable salt thereof.
• the first amount and the second amount together comprise a therapeutically effective amount.
• AZD5305, or a pharmaceutically acceptable salt thereof for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said AZD5305, or a pharmaceutically acceptable salt thereof, and ii) darolutamide, or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• darolutamide for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said darolutamide, or a pharmaceutically acceptable salt thereof, and ii) AZD5305, or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• AZD5305, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC), wherein said treatment comprises the separate, sequential or simultaneous administration of i) said medicament comprising AZD5305, or a pharmaceutically acceptable salt thereof, and ii) darolutamide, or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• the metastatic prostate cancer may be metastatic hormone sensitive prostate cancer (mHSPC) or metastatic castrate resistant prostate cancer (mCRPC).
• mHSPC metastatic hormone sensitive prostate cancer
• mCRPC metastatic castrate resistant prostate cancer
• a pharmaceutical product comprising i) AZD5305 or a pharmaceutically acceptable salt thereof, and ii) darolutamide or a pharmaceutically acceptable salt thereof.
• kits comprising: a first pharmaceutical composition comprising AZD5305, or a pharmaceutically acceptable salt thereof; a second pharmaceutical composition comprising darolutamide, or a pharmaceutically acceptable salt thereof; and instructions for using the first and second pharmaceutical compositions in combination.
• AZD5305 is a selective PARP1 inhibitor.
• selective PARP1 inhibitor it is meant an inhibitor of the PARP enzyme having greater selectivity for PARP1 over other members of the PARP family, such as PARP2, PARP3, PARP5a, and PARP6.
• the selective PARP1 inhibitor has a selectivity for PARP1 over PARP2.
• the selective PARP1 inhibitor has a selectivity for PARP1 over PARP2 which is greater than 5:1.
• the selective PARP1 inhibitor has a selectivity for PARP1 over PARP2 which is greater than 10:1.
• the selective PARP1 inhibitor has a selectivity for PARP1 over PARP2 which is greater than 100: 1.
• a method of treating metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject in need thereof comprising administering to the subject a first amount of a selective PARP1 inhibitor (such as AZD5305), or a pharmaceutically acceptable salt thereof, and a second amount of darolutamide or a pharmaceutically acceptable salt thereof.
• a selective PARP1 inhibitor such as AZD5305
• darolutamide or a pharmaceutically acceptable salt thereof comprising administering to the subject a first amount of a selective PARP1 inhibitor (such as AZD5305), or a pharmaceutically acceptable salt thereof, and a second amount of darolutamide or a pharmaceutically acceptable salt thereof.
• the first amount and the second amount together comprise a therapeutically effective amount.
• a selective PARP1 inhibitor such as AZD5305), or a pharmaceutically acceptable salt thereof, for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said selective PARP1 inhibitor (such as AZD5305), or a pharmaceutically acceptable salt thereof, and ii) darolutamide, or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• darolutamide for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said darolutamide, or a pharmaceutically acceptable salt thereof, and ii) a selective PARP1 inhibitor (such as AZD5305), or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• AZD5305 refers to a compound with the chemical name 5- ⁇ 4-[(7-ethyl-6-oxo-5,6- dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl ⁇ -N-methylpyridine-2-carboxamide and structure shown below:
• AZD5305 is a potent and selective PARP1 inhibitor and PARP1-DNA trapper with excellent in vivo efficacy.
• AZD5305 is highly selective for PARP1 over other PARP family members, with good secondary pharmacology and physicochemical properties and excellent pharmacokinetics in preclinical species, and with reduced effects on human bone marrow progenitor cells in vitro.
• AZD5305 The synthesis of AZD5305 is described in Johannes 2021 and in WO2021/013735, the contents of which are hereby incorporated by reference in their entirety.
• a free base AZD5305 is administered to a subject.
• a pharmaceutically acceptable salt of AZD5305 is administered to a subject.
• crystalline AZD5305 or a pharmaceutically acceptable salt of AZD5305 is administered to a subject.
• dirolutamide refers to a compound with the chemical name / ⁇ /-((S)-1-(3-(3-chloro- 4-cyanophenyl)-1/7-pyrazol-1-yl)propan-2-yl)-5-(1-hydroxyethyl)-1/7-pyrazole-3-carboxamide and structure shown below:
• Darolutamide is an AR antagonist specifically inhibiting AR nuclear translocation. Darolutamide and the active metabolite (ORM-15341) each inhibit wild-type AR as well as clinically relevant AR mutations AR (F876L), which trigger enzalutamide and apalutamide antagonist to agonist switch, as well as AR (W742L) and AR (T877A) which cause bicalutamide agonist switch (Moilanen 2015). Darolutamide has a low potential for drug-drug interaction (Shore 2019) and provides promising reductions in brain penetrance, as well as effectively inhibiting all known AR mutations (Fizazi 2015).
• Darolutamide was approved by the FDA on 30 July 2019 for use in non-metastatic CRPC, based on performance in the ARAMIS trial (NCT02200614) (Fizazi 2019) which showed metastasis free survival was 40.4 months in darolutamide treated patients compared to 18.5 months in placebo treated patients.
• darolutamide The synthesis of darolutamide is described in WO2011/051540, the contents of which are hereby incorporated by reference in its entirety.
• a free base darolutamide is administered to a subject.
• a pharmaceutically acceptable salt of darolutamide is administered to a subject.
• compositions comprising an active ingredient and a pharmaceutically acceptable excipient, carrier or diluent, wherein the active ingredient is AZD5305 or a pharmaceutically acceptable salt thereof, or darolutamide or a pharmaceutically acceptable salt thereof.
• pharmaceutically acceptable excipient, carrier or diluent includes compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, as ascertained by one of skill in the art.
• the pharmaceutical compositions are in solid dosage forms, such as capsules, tablets, granules, powders or sachets.
• the pharmaceutical compositions are in the form of a sterile injectable solution in one or more aqueous or nonaqueous non-toxic parenterally acceptable buffer systems, diluents, solubilizing agents, cosolvents, or carriers.
• a sterile injectable preparation may also be a sterile injectable aqueous or oily suspension or suspension in a non-aqueous diluent, carrier or co-solvent, which may be formulated according to known procedures using one or more of the appropriate dispersing or wetting agents and suspending agents.
• the pharmaceutical compositions could be a solution for iv bolus/infusion injection or a lyophilized system (either alone or with excipients) for reconstitution with a buffer system with or without other excipients.
• the lyophilized freeze-dried material may be prepared from non-aqueous solvents or aqueous solvents.
• the dosage form could also be a concentrate for further dilution for subsequent infusion.
• the language “treat,” “treating” and “treatment” includes the reduction or inhibition of enzyme or protein activity related to PARP-1, AR or metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, amelioration of one or more symptoms of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, or the slowing or delaying of progression of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject.
• the language “treat,” “treating” and “treatment” also includes the reduction or inhibition of the growth of a tumor or proliferation of cancerous cells in a subject.
• the language “inhibit”, “inhibition” or “inhibiting” includes a decrease in the baseline activity of a biological activity or process.
• the term “subject” includes warm-blooded mammals, for example, primates, dogs, cats, rabbits, rats, and mice.
• the subject is a primate, for example, a human.
• the subject is suffering from metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC).
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• terapéuticaally effective amount includes that amount of AZD5305 and that amount of darolutamide which together will elicit a biological or medical response in a subject, for example, the reduction or inhibition of enzyme or protein activity related to PARP1, AR, or cancer; amelioration of symptoms of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC); or the slowing or delaying of progression of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC).
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• the language “therapeutically effective amount” includes the amount of AZD5305 and darolutamide together that is effective to at least partially alleviate, inhibit, and/or ameliorate metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) or inhibit PARP1 or AR, and/or reduce or inhibit the growth of a tumor or proliferation of cancerous cells in a subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• PARP1 or AR inhibit the growth of a tumor or proliferation of cancerous cells in a subject.
• a method of treating metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject in need thereof comprising administering to the subject a first amount of AZD5305 or a pharmaceutically acceptable salt thereof, and a second amount of darolutamide or a pharmaceutically acceptable salt thereof.
• the first amount and the second amount together comprise a therapeutically effective amount.
• AZD5305, or a pharmaceutically acceptable salt thereof for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said AZD5305, or a pharmaceutically acceptable salt thereof, and ii) darolutamide, or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• darolutamide for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said darolutamide, or a pharmaceutically acceptable salt thereof, and ii) AZD5305, or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• AZD5305, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of metastatic prostate cancer, hormone sensitive prostate cancer (HSPC) or castrate resistant prostate cancer (CRPC) in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said medicament comprising AZD5305, or a pharmaceutically acceptable salt thereof, and ii) darolutamide, or a pharmaceutically acceptable salt thereof, to said subject.
• HSPC hormone sensitive prostate cancer
• CRPC castrate resistant prostate cancer
• AZD5305 or a pharmaceutically acceptable salt thereof and darolutamide or a pharmaceutically acceptable salt thereof are administered separately, sequentially or simultaneously in a treatment cycle. In some embodiments, AZD5305 or a pharmaceutically acceptable salt thereof is continuously administered in the treatment cycle and darolutamide or a pharmaceutically acceptable salt is also continuously administered in the treatment cycle.
• continuous refers to administration of a therapeutic agent, e.g. AZD5305, at regular intervals without stopping or interruption, i.e. , no void day.
• void day it is meant a day when a therapeutic agent is not administered.
• a “cycle”, “treatment cycle” or “dosing schedule”, as used herein, refers to a period of combination treatment that is repeated on a regular schedule.
• the treatment can be given for one week, two weeks, or three weeks wherein AZD5305 and darolutamide are administered in a coordinated fashion.
• a treatment cycle is about 1 week to about 3 months.
• a treatment cycle is about 5 days to about 1 month.
• a treatment cycle is about 1 week to about 3 weeks.
• a treatment cycle is about 1 week, about 10 days, about 2 weeks, about 3 weeks, about 4 weeks, about 2 months, or about 3 months.
• AZD5305 or a pharmaceutically acceptable salt thereof and darolutamide or a pharmaceutically acceptable salt thereof are administered to the human subject in one or more treatment cycles, e.g., a treatment course.
• a “treatment course” comprises multiple treatment cycles, which can be repeated on a regular schedule, or adjusted as a tapered schedule as the patient’s disease progression is monitored.
• a patient's treatment cycles can have longer periods of treatment and/or shorter periods of rest at the beginning of a treatment course (e.g. , when the patient is first diagnosed), and as the cancer enters remission, the rest period lengthens, thereby increasing the length of one treatment cycle.
• the period of time for treatment and rest in a treatment cycle, the number of treatment cycles, and the length of time for the treatment course can be determined and adjusted throughout the treatment course by the skilled artisan based on the patient’s disease progression, treatment tolerance, and prognosis.
• the method comprises 1 to 10 treatment cycles. In some embodiments, the method comprises 2 to 8 treatment cycles.
• AZD5305 or a pharmaceutically acceptable salt thereof is administered for 28 days in a 28-day treatment cycle
• darolutamide or a pharmaceutically acceptable salt thereof is administered for 28 days in the 28-day treatment cycle.
• AZD5305 or a pharmaceutically acceptable salt thereof is administered orally. In some embodiments, AZD5305 or a pharmaceutically acceptable salt thereof is in tablet dosage form. In some embodiments, AZD5305 is administered in a dose of up to about 60 mg (for example, up to about 5 mg, up to about 10 mg, up to about 15 mg, up to about 20 mg, up to about 25 mg, up to about 30 mg, up to about 35 mg, up to about 40 mg, up to about 45 mg, up to about 50 mg, up to about 55 mg, or up to about 60 mg AZD5305) per day. In some embodiments, AZD5305 is administered once a day (QD).
• QD a day
• AZD5305 is administered in a dose of about 10 mg QD, about 15 mg QD, about 20 mg QD, about 25 mg QD, about 30 mg QD, about 35 mg QD, about 40 mg QD, about 45 mg QD, about 50 mg QD, about 55 mg QD or about 60 mg QD.
• AZD5305 is administered in a dose of up to about 140 mg (for example, up to about 80 mg, up to about 90 mg, up to about 100 mg, up to about 110 mg, up to about 120 mg, or up to about 140 mg AZD5305) per day. In some further embodiments, AZD5305 is administered in a dose of about 80 mg QD, about 90 mg QD, about 100 mg QD, about 110 mg QD, about 120 mg QD, or about 140 mg QD.
• darolutamide or a pharmaceutically acceptable salt thereof is administered orally. In some embodiments, darolutamide or a pharmaceutically acceptable salt thereof is in tablet dosage form. In some embodiments, darolutamide or a pharmaceutically acceptable salt thereof is administered in a dose of about 600 mg orally twice per day (BID). In some embodiments, the 600 mg dose comprise two 300 mg tablets. In some embodiments, AZD5305 and darolutamide are taken separately, where a dose of AZD5305 is taken on an empty stomach, with no food two hours before, and a dose of darolutamide is taken at least one hour after AZD5305 with food.
• a pharmaceutical product comprising i) AZD5305 or a pharmaceutically acceptable salt thereof, and ii) darolutamide or a pharmaceutically acceptable salt thereof.
• AZD5305 or a pharmaceutically acceptable salt thereof, and darolutamide or a pharmaceutically acceptable salt thereof are present in a single dosage form.
• AZD5305 or a pharmaceutically acceptable salt thereof, and darolutamide or a pharmaceutically acceptable salt thereof are present separate dosage forms.
• kits comprising: a first pharmaceutical composition comprising AZD5305, or a pharmaceutically acceptable salt thereof; a second pharmaceutical composition comprising darolutamide, or a pharmaceutically acceptable salt thereof; and instructions for using the first and second pharmaceutical compositions in combination.
• Metastatic prostate cancer refers to prostate cancer which has spread or metasised to another part of the body.
• HSC Hormone sensitive prostate cancer
• Castrate resistant prostate cancer refers to prostate cancer which continues to grow even when androgen levels in the body are extremely low or undetectable.
• Metastatic hormone sensitive prostate cancer refers to prostate cancer which has spread or metasised to another part of the body, and whose growth is inhibited by a decrease in androgen levels or by inhibiting androgen action.
• mCRPC Metastatic castrate resistant prostate cancer
• treatment with a luteinising hormone-releasing hormone (LHRH) agonist or antagonist may be administered concurrently, especially if the patient has not undergone an orchidectomy or a subcapsular orchidectomy.
• LHRH agonists include leuprolide/leuprorelin, goserelin, triptorelin, histrelin, and buserelin.
• LHRH antagonists include degarelix, relugolix, bicalutamide, flutamide and cyproterone acetate. Such additional treatments may be dosed at the current standard of care.
• AZD5305 may be beneficial as PARP1 is a positive co-regulator of the AR-driven gene expression of AR targets, in addition to its role in DNA repair.
• AZD5305 should further inactivate the androgen receptor pathway, adding to the effect of darolutamide.
• NHAs New Hormonal Agents
• AZD5305 a selective PARP-1 inhibitor
• the prostate cancer treated may be deficient in Homologous Recombination (HR) dependent DNA DSB repair activity.
• HR Homologous Recombination
• the HR dependent DNA DSB repair pathway repairs double-strand breaks (DSBs) in DNA via homologous mechanisms to reform a continuous DNA helix (Khanna and Jackson 2001).
• the components of the HR dependent DNA DSB repair pathway include, but are not limited to, ATM (NM_000051), RAD51 (NM_002875), RAD51 L1 (NM_002877), RAD51C (NM_002876), RAD51L3 (NM_002878), DMC1 (NM_007068), XRCC2 (NM_005431), XRCC3 (NM_005432), RAD52 (NM_002879), RAD54L (NM_003579), RAD54B (NM_012415), BRCA1 (NM_007295), BRCA2 (NM_000059), RAD50 (NM_005732), MRE11A (NM_005590) and NBS1 (NM_002485).
• Other proteins involved in the HR dependent DNA DSB repair pathway include regulatory factors such as EMSY (Hughes-Davies 2003). HR components are also described in Wood 2001.
• a prostate cancer which is deficient in HR dependent DNA DSB repair may comprise or consist of one or more cancer cells which have a reduced or abrogated ability to repair DNA DSBs through that pathway, relative to normal cells i.e. the activity of the HR dependent DNA DSB repair pathway may be reduced or abolished in the one or more cancer cells.
• the activity of one or more components of the HR dependent DNA DSB repair pathway may be abolished in the one or more prostate cancer cells of an individual having a prostate cancer which is deficient in HR dependent DNA DSB repair.
• Components of the HR dependent DNA DSB repair pathway are well characterised in the art (see for example, Wood 2001) and include the components listed above.
• the prostate cancer cells may have a BRCA1 and/or a BRCA2 deficient phenotype i.e. BRCA1 and/or BRCA2 activity is reduced or abolished in the prostate cancer cells.
• Prostate cancer cells with this phenotype may be deficient in BRCA1 and/or BRCA2, i.e. expression and/or activity of BRCA1 and/or BRCA2 may be reduced or abolished in the prostate cancer cells, for example by means of mutation or polymorphism in the encoding nucleic acid, or by means of amplification, mutation or polymorphism in a gene encoding a regulatory factor, for example the EMSY gene which encodes a BRCA2 regulatory factor (Hughes-Davies 2003).
• BRCA1 and BRCA2 are known tumour suppressors whose wild-type alleles are frequently lost in tumours of heterozygous carriers (Jasin 2002; Tutt 2002).
• the individual is heterozygous for one or more variations, such as mutations and polymorphisms, in BRCA1 and/or BRCA2 or a regulator thereof.
• variations such as mutations and polymorphisms
• the detection of variation in BRCA1 and BRCA2 is well-known in the art and is described, for example in EP 699 754, EP 705 903, Neuhausen and Ostrander 1992; Chumbles and Foulkes 2002; Janatova 2003; Jancarkova 2003). Determination of amplification of the BRCA2 binding factor EMSY is described in Hughes-Davies 2003.
• Mutations and polymorphisms associated with cancer may be detected at the nucleic acid level by detecting the presence of a variant nucleic acid sequence or at the protein level by detecting the presence of a variant (i.e. a mutant or allelic variant) polypeptide.
• Example 1 Efficacy of AZD5305 combined with darolutamide in an in vitro assay
• Cell line identification was validated using the CellCheck assay (IDEXX Bioanalytics, Westbrook, ME, USA). All cell lines were validated free of virus Mycoplasma contamination using the MycoSEQ assay (Thermo Fisher Scientific, Waltham, MA, USA) or STAT-Myco assay (IDEXX Bioanalytics). All cell lines were grown RPMI-1640 growth media (Corning 17- 105-CV) supplemented with 10% fetal bovine serum (FBS) or, when indicated, 10% charcoal stripped FBS (ThermoFisher Scientific, 12676029) and 2 mM glutamine.
• FBS fetal bovine serum
• charcoal stripped FBS ThermoFisher Scientific, 12676029
• Cells in 384-well or 96-well plates were dosed using an Echo 555 (LabCyte, San Jose, CA, USA) or using the HP D300e Digital Dispenser (HP Life Science Dispensing), respectively. Live cell count pre- and post-treatment (7 days after treatment) was determined using CellTiter-Glo as per manufacturer’s instructions (Promega, Madison, Wl, USA; G7570).
• Monotherapy agent potency is expressed in M concentrations; values are the mean of two independent experiments each performed in triplicate. HSA (Highest Single Agent) is the synergy score mean of three independent experiments each performed in triplicate. SD indicate standard deviation error, where not indicated only one experiment was performed.
• ST1273PDX model ( ⁇ 70 mg tumour fragments) will be implanted subcutaneously onto the flank of athymic nude male mice (aged 6-12 weeks). When tumours reach approximately ISOSOO mm 3 , 32 mice with the most similar sized tumours will be randomly assigned to treatment groups as demonstrated in the table below.
• mice will be dosed for 28 days, with the dose calculated for individual animals on day of dosing, and with a 10mg/kg dosing volume.
• the bodyweight of all mice in the study will be measured and recorded 2 times per week; this information will be used to calculate precise dosing for each animal.
• metastatic status is defined as at least one documented metastatic lesion on either bone scan or CT/MRI scan.
• Patients with mCRPC should have documented prostate cancer progression at screening as assessed by the Investigator with at least one of the following:
• PSA prostate-specific antigen progression defined by a minimum of 3 rising PSA levels with an interval of > 1 week between each determination.
• the PSA value at the screening visit should be > 1 pg/L (1 ng/mL).
• Patients with mCRPC should be either first or second line in the castrate resistant setting (should have received ⁇ 1 prior line of systemic therapy). Androgen deprivation therapy does not count as a line of therapy. Docetaxel that was previously used when the patient was in the hormone sensitive stage of their disease would not count as a line of therapy. or
• Patients may have received disease-related radiation or surgery; which should have been completed at least 4 weeks prior to enrolment.
• Adequate organ and marrow function in the absence of transfusions or growth factor support within 14 days prior to enrolment: can only be enrolled if total bilirubin level is ⁇ 1.5 x ULN.
• ALT alanine transaminase
• AST aspartate transaminase
• INR international normalized ratio
• ULN upper limit normal.
• the starting dose of AZD5305 will be 60 mg once daily (QD). Darolutamide will be dosed at 600 mg twice daily (BD) with concurrent dosing of AZD5305 in combination with darolutamide from day 1 of cycle 1 .
• the cycle length will be 28 days, with AZD5305 being dosed once daily, and darolutamide being dosed twice daily at 600 mg.
• AZD5305 will be taken on an empty stomach with no food for 2 hours and 1 hour after, with darolutamide being taken with food at least one hour after the daily dose of AZD5305.
• the 600mg dose of darolutamide will be taken as two 300 mg film-coated tablets.
• the dose may be escalated to 90 mg QD if required (whilst the darolutamide dose will be maintained at 600 mg BD), and if not tolerated, the AZD5305 dose will be de-escalated to 40 mg QD.
• the dose of AZD5305 may be further escalated, up to no more than 140 mg QD.
• the dose of AZD5305 may be de-escalated to 20 mg QD, either due to tolerability or if such dose is shown to be effective.
• All potential dose escalation and/or de-escalation levels after the starting dose may be adjusted in light of emerging safety, tolerability and/or PK data.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=86185292

Family Applications (1)

Country Status (11)

Cited By (1)

Citations (5)

• 2023
  • 2023-04-06 WO PCT/EP2023/059126 patent/WO2023194528A1/en not_active Ceased
  • 2023-04-06 US US18/853,491 patent/US20250235448A1/en active Pending
  • 2023-04-06 AU AU2023248685A patent/AU2023248685A1/en active Pending
  • 2023-04-06 KR KR1020247036943A patent/KR20240170956A/ko active Pending
  • 2023-04-06 CN CN202380032429.6A patent/CN118973572A/zh active Pending
  • 2023-04-06 CA CA3254948A patent/CA3254948A1/en active Pending
  • 2023-04-06 JP JP2024559034A patent/JP2025511401A/ja active Pending
  • 2023-04-06 EP EP23719307.3A patent/EP4504180A1/en active Pending
  • 2023-04-06 IL IL316016A patent/IL316016A/en unknown
  • 2023-04-07 TW TW112112999A patent/TW202404593A/zh unknown
• 2024
  • 2024-10-04 MX MX2024012368A patent/MX2024012368A/es unknown

Patent Citations (5)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events